This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Halozyme Therapeutics, Inc.
Drug Names(s): rHuCAT-L
Description: HTI-501 is a recombinant human proteinase known as cathepsin-L (rHuCAT-L). As a conditionally active biologic, HTI-501 is designed to allow local degradation of the collagenous fibrous components of the extracellular matrix at the injection site by tightly controlling the extent and duration of enzyme activity once injected into the body.
Additional information available to subscribers only: